aap Implantate AG

M&A Activity • Mar 22, 2016

News Details

Ad-hoc | 22 March 2016 02:21

aap Implantate AG: aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies

aap Implantate AG / Key word(s): Disposal/Change in Forecast

22.03.2016 02:21

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc-Announcement according to § 15 WpHG

aap sells biomaterials business for EUR 36 million and becomes a pure
player in trauma with innovative technologies

• Closing of the transaction will lead to adjustment of 2016 guidance;
  Postponement of publication of consolidated and annual financial statements
  2015 -

Berlin, 22 March 2016

aap Implantate AG ("aap") signed a notarized share purchase agreement today
with a leading European private equity firm for the sale of 100% of the
company shares in its subsidiary aap Biomaterials GmbH, which has its
registered office in Dieburg. The purchase price is based on an assumed
enterprise value of aap Biomaterials GmbH of EUR 36 million and will be due
for payment after closing of the transaction. The closing of the
transaction is subject to the market standard conditions precedent, which
are to be met within the next three months. Upon closing of the
transaction, the existing profit and loss transfer agreement between aap
and aap Biomaterials GmbH will be terminated.

The operation sold within the transaction (discontinued operation) consists
of aap Biomaterials GmbH, which is specialized in the development,
production and marketing of bone cements, mixing systems and related
accessories, and aap's distribution business in this area. In 2015, the
operation sold recorded sales based on preliminary figures amounting to EUR
16.0 million.

The closing of the transaction will result in a positive one-time
deconsolidation effect on the earnings level. The company plans to use part
of the proceeds to finance further growth and to distribute part of them to
its shareholders.

The complete consolidated and annual financial statements as of 31 December
2015 of aap will be published by 29 April 2016 the latest. The reason for
the delay in the publication is the sale of aap Biomaterials GmbH, which
must already be stated as a so-called discontinued operation in the
consolidated financial statements for 2015. This leads to extensive
reporting requirements in the notes and the management report as well as in
various presentations of results in the consolidated financial statements.

Upon closing of the transaction, aap's previous sales and EBITDA forecast
for the 2016 financial year will be no longer valid. The company will
publish a new and updated guidance for the current financial year after
closing. In this context, aap aims to announce also further details
regarding the use of a part of the proceeds for the benefit of the
shareholders.

The closing of the transaction is the last step in the transformation of
aap from a general medtech company to a pure player in trauma.

Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099
Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290;
f.franke@aap.de

22.03.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart

End of Announcement DGAP News-Service

---